



GIOVANNI DAMIANO ALETTI

Italy

Personal statement

I am deeply motivated to contribute to the ESGO Council, bringing more than twenty years of experience as a clinician, academic, and educator in gynecologic oncology. As Director of Surgical Gynecology at the Istituto Europeo di Oncologia in Milan and Associate Professor at the University of Milan, I have dedicated my career to improving the quality, safety, and outcomes of oncologic surgery for women with gynecologic cancers. These roles have given me a comprehensive understanding of multidisciplinary care, surgical innovation, and the practical challenges of maintaining excellence in complex clinical environments.

My academic background and research activity align closely with ESGO's mission to advance science and education in gynecologic oncology. I have authored over one hundred publications, led translational and clinical research projects, and supervised numerous trainees and fellows, including within ESGO and ESAGON-accredited programs.

My early experience at the Mayo Clinic and subsequent collaborations in Europe and the United States have strengthened my commitment to fostering international exchange and the dissemination of best practices. Education and mentorship are at the heart of my professional motivation.

I believe that developing the next generation of gynecologic oncologists requires not only surgical skill but also ethical awareness, empathy, and teamwork. Through structured training and personal mentorship, I aim to promote these values and help ESGO expand its educational initiatives and mentorship frameworks.

As a member of the Council, I would contribute my experience in surgical leadership and academic coordination to ESGO's key priorities-enhancing accreditation processes, supporting the development of clinical guidelines, and promoting high-quality, collaborative research.

I am also deeply committed to strengthening ESGO's partnerships with patient organizations and international health bodies such as WHO, ensuring that our work remains patient-centered and globally relevant. I share ESGO's vision of excellence through collaboration, education, and research. My motivation to join the Council stems from a sincere desire to serve the gynecologic oncology community, to uphold the highest standards of care, and to advance ESGO's mission of improving women's cancer outcomes across Europe and beyond.

Education

Medical Degree in Medicine and Surgery, University of Milan, Milan, Italy (1998)

Residency in Obstetrics and Gynecology, San Raffaele University, Milan, Italy (2004)

Research Fellowship in Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota, USA (2003–2004)

Clinical Fellowship in Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota, USA (2006–2009)

National Scientific Qualification, Academic Field 06/H1 – Full Professor, Italian Ministry of University and Research, (2024)

Current position

Director at the Division of Surgical Gynecology, European Institute of Oncology (IEO), Milan (since 2024)

Director of the ESGO-accredited Gynecologic Oncology Fellowship, IEO, Milan

Surgical Tutor, ESAGON (European School of Abdominal Pelvic Surgery), IEO, Milan (since 2009)

Associate Editor of the International Journal of Gynecological Cancer (since 2024)

Editorial Board Member of Gynecologic Oncology journal (since 2012)

Academic roles

Associate Professor of Obstetrics and Gynecology, University of Milan (since 2018)

Professor of Obstetrics and Gynecology within the Medicine and Surgery Degree Course, University of Milan (since 2018)

Professor of Gynecologic Oncology, Residency Program in Obstetrics and Gynecology, University of Milan (since 2017)

Professor of Gynecologic Oncology, Residency Program in Medical Oncology, University of Milan (since 2017)

Students' and residents' **thesis advisor** at the University of Milan

Publication and research achievement

133 peer reviewed publication, H-index: 45

10 book chapter

Italian principal investigator of the TRUST trial (Trial of radical upfront surgical therapy in advanced ovarian cancer NCT02828618)

Grant awarded

Principal Investigator: Investigating the Heterogeneity of Endometrial Cancer through Molecular Biology and Artificial Intelligence

Funded by Fondazione IEO-Monzino (€327,811); Period: Jan 2025 – Dec 2026

Principal Investigator: Defining the Role of Molecular Characterization in Advanced and Clear Cell Endometrial Cancer Patients: An Innovative Approach to Tailor Adjuvant Treatment

Funded by Italian Ministry of University and Research – PRIN 2022 (€180,000); Period: Feb 2025 – Feb 2027

Co-Principal Investigator: Understanding Ovarian Cancer Initiation and Progression through Explainable AI (Under-XAI)

Funded by Italian Ministry of Health – PNRR (M6/C2_CALL2022) (€1,000,000); Period: Apr 2023 – May 2025

Co-Investigator: PREDICT – Predictive Response and Disease Evolution in Ovarian Cancer with

Generative AI

Funded by Fondazione Regione Lombardia (€1,800,000); Period: 2025–2028

ESGO activities

Member of the ESGO Committee for the Development of Quality Indicators in Advanced Ovarian Cancer Surgery (since 2015)

Working Group **Expert**, ESGO Ovarian Cancer Guidelines (since 2017)

Surgical Tutor within the ESGO-accredited Gynecologic Oncology Fellowship at IEO (since 2012) and current **Director** of the Fellowship Program.

Book Chapters

1. Aletti G . **Surgery for Ovarian Cancer**. Morrow CP *Morrow's Gynecologic Cancer Surgery*, Second Edition, © C. Paul Morrow, 2013
2. Aletti GD, Cliby WA. **Primary Cytoreduction: Factors Impacting Operability and the Extent of Surgery**. Ayhan A, Reed N, Gultekin M, Dursun P. *Textbook of Gynecologic Oncology*, Second Edition. Günes publishing, 2012
3. Aletti GD, Cliby WA. **Preoperative risk stratification and intraoperative supportive care**. Bristow RE, Karlan BY, Chi DS. *Surgery for Ovarian Cancer*, Third Edition. CRC Press, Taylor & Francis Group, 2016
4. Aletti GD, Cliby WA. **Primary Cytoreduction: Factors Impacting Operability and the Extent of Surgery**. Ayhan A, Reed N, Gultekin M, Dursun P. *Textbook of Gynecologic Oncology*, Third Edition. Günes publishing
5. Aletti GD, Carinelli S. **Histopathology of gynaecological cancers**. Du Bois A, Hall M, Fotopoulou C, *ESMO Gynecological Tumours Essentials*, ESMO press
6. Aletti GD, Minig L, Zanagnolo V. **Radical Pelvic and Retroperitoneal Surgery**. Ramirez P, Frumovitz M, Abu-Rustum N. *Principles of Gynecologic Oncology Surgery*, 1st Edition, Elsevier
7. Aletti GD, Multinu F, Achilarte MT, Garbi A. **Razionale e tecnica chirurgica del retroperitoneale in ginecologia oncologica** Scambia, Scollo, Vizza e Ghezzi, *Trattato di chirurgia ostetrica e ginecologica*, EDRA
8. Aletti GD, Cliby WA. **Primary Cytoreduction: Factors Impacting Operability and the Extent of Surgery**. Ayhan A, Reed N, Gultekin M, Dursun P. *Textbook of Gynecologic Oncology*, Fourth Edition. Günes publishing, 2017
9. Aletti GD, Multinu F, Cliby WA. **Preoperative risk stratification and intraoperative supportive care**. Bristow RE, Karlan BY, Chi DS. *Surgery for Ovarian Cancer*, Fourth Edition. CRC Press, Taylor & Francis Group, 2022
10. Aletti GD, Minig L, Zanagnolo V. **Radical Pelvic and Retroperitoneal Surgery**. Ramirez P, Frumovitz M, Abu-Rustum N. *Principles of Gynecologic Oncology Surgery*, 2nd Edition, Elsevier

Articles

1. Frigerio L, Mariani A, Gandini L, Origoni M, Galli L, Rabaiotti E, Aletti G, Ferrari A. **Prognostic Factors in Patients with Locally Advanced Cervical Cancer Treated with Radical Hysterectomy and Adjuvant Radiotherapy.** Int Surg, 1998; 83: 265-270.
2. Sier CFM, Sidenius N, Mariani A, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brunner N, Blasi F. **Presence of Urokinase-Type Plasminogen Activator Receptor in Urine of Cancer Patients and Its Possible Clinical Relevance.** Lab Invest, 1999; 79(6): 717-722.
3. Quellari P, Mariani A, Aletti G, Villa G, Filippis S, Viganò R, Frigerio LG, Ferrari AG. **Polytetrafluoroethylene Mesh For Abdominal Hysterosacropexy: Long-Term Outcome Of A Conservative Approach Of Utero-Vaginal Prolapse.** Eur J Pelvic Surg, 1999; 2(1): 35-41
4. Frigerio L, Mangili G, Aletti G, Carnelli M, Garavaglia E, Beatrice S, Ferrari A. **Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.** Gynecol Oncol. 2001;81(1):53-7.
5. Picchio M, Sironi S, Messa C, Mangili G, Landoni C, Gianolli L, Zangheri B, Vigano R, Aletti G, de Marzi P, De Cobelli F, Del Maschio A, Ferrari A, Fazio F. **Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.** Q J Nucl Med. 2003;47(2):77-84
6. Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N. **Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice.** Thromb Haemost. 2004; 91(2):403-11
7. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, Vigano R, Picchio M, Taccagni G, Maschio AD, Fazio F. **Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings.** Radiology. 2004;233(2):433-40.
8. Mangili G, Aletti G, Frigerio L, Franchi M, Panacci N, Vigano R, DE Marzi P, Zanetto F, Ferrari A. **Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis.** Int J Gynecol Cancer. 2005;15(5):830-5
9. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA. **Aggressive surgical effort and improved survival in advanced-stage ovarian cancer.** Obstet Gynecol. 2006;107(1):77-85.
10. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. **Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.** Gynecol Oncol. 2006; 100(2):283-7.
11. Aletti GD, Gostout BS, Podratz KC, Cliby WA. **Ovarian cancer surgical resectability: relative impact of disease, patient status and surgeon.** Gynecol Oncol. 2006;100(1):33-7.
12. Aletti GD, Cliby WA. **Importance of surgical aggressiveness in advanced ovarian cancer.** J Clin Oncol. 2006; 20;24(15):2397.
13. Aletti GD, Cliby WA. **Is aggressive surgery beneficial only for patients with less advanced ovarian cancer? A commentary on the international comparison within the SCOTROC-1 trial .** Am J Oncol Rev. 2006; 5 (4): 200-202

14. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. **Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.** J Clin Invest. 2006; 116(7):1994-2004.
15. Aletti GD, Podratz KC, Jones MB, Cliby WA. **Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer.** J Am Coll Surg. 2006; 203(4):521-6.
16. Aletti GD, Long HJ, Podratz KC, Cliby WA. **Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?** Gynecol Oncol. 2007; 104(1):212-6.
17. Cliby WA, Aletti GD, Wilson TO, Podratz KC. **Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?** Gynecol Oncol. 2006;103(3):797-801.
18. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. **Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.** Am J Obstet Gynecol. 2006;195(6):1862-8.
19. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. **Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system.** Gynecol Oncol. 2007;105(1):84-9.
20. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J, Shridhar V. **Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance.** Oncogene. 2007; 26;26(34):4969-78.
21. Cliby W, Aletti G. **Surgical Management of Diaphragm Disease in Ovarian Cancer.** Operative Techniques in General Surgery, 2007; 9(2); 61-9.
22. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. **Current Management Strategies for Ovarian Cancer.** Mayo Clin Proc. 2007; 82(6):751-770.
23. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, Bristow RE, Chi DS, Cliby WA. **A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.** Gynecol Oncol. 2007;107(1):99-106.
24. Chien J, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC. **Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.** J Cell Biochem. 2007; 1;102(5):1117-29.
25. Dearing AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. **How Relevant Are ACOG and SGO Guidelines for Referral of Adnexal Mass?** Obstet Gynecol. 2007;110(4):841-8.
26. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. **Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.** Am J Obstet Gynecol. 2007; 197(6):676.e1-7.
27. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA. **Müllerian inhibiting substance type II receptor (MISIR): A novel, tissue-specific target expressed by gynecologic cancers.** Gynecol Oncol. 2008;108(1):141-8
28. Mangili G, Montoli S, De Marzi P, Sassi I, Aletti G, Aletti G, Taccagni G. **The role of DNA ploidy in postoperative management of stage I endometrial cancer.** Ann Oncol. 2008;19(7):1278-83.

29. Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W. **Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma.** Gynecol Oncol. 2008;109(2):303-7.
30. Aletti GD, Cliby WA. **Primary Cytoreduction in Advanced Ovarian Cancer: "Biological and Surgical Aggressiveness"** Oncology. 2008; 22 (9): 1041-1045
31. Dowdy SC, Aletti G, Cliby WA, Podratz KC, Mariani A. **Extra-peritoneal laparoscopic para-aortic lymphadenectomy - A prospective cohort study of 293 patients with endometrial cancer.** Gynecol Oncol. 2008;111(3):418-24.
32. Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O'Malley DM, Cliby WA. **Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer.** Obstet Gynecol. 2009;113(1):11-17.
33. Aletti GD, Podratz KC, Cliby WA, Gostout BS. **Stage IV ovarian cancer: Disease site-specific rationale for postoperative treatment.** Gynecol Oncol. 2009;112(1):22-7.
34. Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long CH, **Aggressive and Complex Surgery for Advanced Ovarian Cancer: An Economic Analysis.** Gynecol Oncol. 2009;112(1):16-21.
35. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, Podratz KC, Cliby WA. **Quality improvement (QI) in the surgical approach to advanced ovarian cancer (OC): the Mayo Clinic experience.** J Am Coll Surg. 2009; 208 (4): 614-620
36. Aletti GD, Powless C, Bakkum-Gamez J, Wilson TO, Podratz KC, Cliby WA. **Pattern of retroperitoneal dissemination of primary peritoneum cancer: Basis for rational use of lymphadenectomy.** Gynecol Oncol. 2009;114(1):32-6.
37. Uccella S, Podratz KC, Aletti GD, Mariani A. **Lymphadenectomy in endometrial cancer.** Lancet. 2009;373(9670):1170; author reply 1170-1.
38. Chien J, Ota T, Aletti G, Shridhar R, Boccellino M, Quagliuolo L, Baldi A, Shridhar V. **Serine protease HtrA1 associates with microtubules and inhibits cell migration.** Mol Cell Biol. 2009; 29(15):4177-87.
39. Uccella S, Podratz KC, Aletti GD, Mariani A. **Re: Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial.** 2009; 16;101(12):897-8.
40. Powless CA, Bakkum-Gamez JN, Aletti GD, Cliby WA. **Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration.** Gynecol Oncol. 2009;115(1):86-9.
41. Heisler CA, Aletti GD, Weaver AL, Melton LJ 3rd, Cliby WA, Gebhart JB. **Improving quality of care: development of a risk-adjusted perioperative morbidity model for vaginal hysterectomy.** Am J Obstet Gynecol. 2010; 202(2):137.e1-5.
42. Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA. **From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.** Ann Oncol. 2010;21(9):1772-8.
43. Aletti GD, Hartmann LC. **Ovarian cancer care: it's time for "personalized" approaches.** Oncology

(Williston Park). 2010;24(8):728

44. Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi R, Radice D, Maggioni A. **Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.** Gynecol Oncol. 2010;119(2):259-64.
45. Zapardiel I, Rosenberg P, Peiretti M, Zanagnolo V, Sanguineti F, Aletti G, Landoni F, Bocciolone L, Colombo N, Maggioni A. **The role of restaging borderline ovarian tumors: single institution experience and review of the literature.** Gynecol Oncol. 2010;119(2):274-7.
46. Aletti GD, Eisenhauer EL, Santillan A, Axtell A, Aletti G, Holschneider C, Chi DS, Bristow RE, Cliby WA. **Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment.** Gynecol Oncol. 2011;120(1):23-8.
47. Bakkum-Gamez JN, Richardson DL, Seamon LG, Aletti GD, Powless CA, Keeney GL, O'Malley DM, Cliby WA. **Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?** Int J Gynecol Cancer. 2010; 20(7):1125-31.
48. Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. **Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical staging.** Gynecol Oncol. 2011;122(3):536-40.
49. Zecchini S, Bombardelli L, Decio A, Bianchi M, Mazzarol G, Sanguineti F, Aletti G, Maddaluno L, Berezin V, Bock E, Casadio C, Viale G, Colombo N, Giavazzi R, Cavallaro U. **The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling.** EMBO Mol Med. 2011; 3(8):480-94.
50. Langstraat C, Aletti GD, Cliby WA. **Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: A delicate balance requiring individualization.** Gynecol Oncol. 2011;123(2):187-91.
51. Zapardiel I, Peiretti M, Zanagnolo V, Biffi R, Bocciolone L, Landoni F, Aletti G, Colombo N, Maggioni A. **Diaphragmatic surgery during primary cytoreduction for advanced ovarian cancer: peritoneal stripping versus diaphragmatic resection.** Int J Gynecol Cancer. 2011; 21(9):1698-703.
52. Cliby W, Aletti G, Chi D, Bristow R. **RE: Defining the limits of radical cytoreductive surgery in ovarian cancer.** Gynecol Oncol. 2012;125(2):509-10; author reply 508-9.
53. Ceccaroni M, Roviglione G, Spagnolo E, Casadio P, Clarizia R, Peiretti M, Bruni F, Peters I, Aletti G. **Pelvic Dysfunctions and Quality of Life after Nerve-sparing Radical Hysterectomy: A Multicenter Comparative Study.** Anticancer Res. 2012; 32(2):581-8.
54. Moslemi-Kebria M, El-Nashar SA, Aletti GD, Cliby WA. **Intraoperative hypothermia during cytoreductive surgery for ovarian cancer and perioperative morbidity.** Obstet Gynecol. 2012;119(3):590-6.
55. Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A. **Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes.** Gynecol Oncol. 2012;126(2):220-3
56. Kalogera E, Dowdy SC, Mariani A, Aletti G, Bakkum-Gamez JN, Cliby WA. **Utility of Closed Suction Pelvic**

Drains at Time of Large Bowel Resection for Ovarian Cancer. Gynecol Oncol. 2012;126(3):391-6

57. Zapardiel I, Peiretti M, Zanagnolo V, Biffi R, Bocciolone L, Landoni F, Aletti G, Colombo N, Maggioni A. **Splenectomy as part of primary cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study.** Int J Gynecol Cancer. 2012;22(6):968-73.
58. Landoni F, Zanagnolo V, Rosenberg PG, Lopes A, Radice D, Bocciolone L, Aletti G, Parma G, Colombo N, Maggioni A. **Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience.** Gynecol Oncol. 2013; 130(1):69-74
59. Kalogera E, Dowdy SC, Mariani A, Weaver AL, Aletti G, Bakkum-Gamez JN, Cliby WA. **Multiple large bowel resections: Potential risk factor for anastomotic leak.** Gynecol Oncol. 2013;130(1):213-8.
60. Glaser G, Torres M, Kim B, Aletti G, Weaver A, Mariani A, Hartmann L, Cliby W. **The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.** Gynecol Oncol. Gynecol Oncol. 2013;130(2):280-3
61. Zanagnolo V, Rollo D, Tomaselli T, Rosenberg PG, Bocciolone L, Landoni F, Aletti G, Peiretti M, Sanguineti F, Maggioni A. **Robotic-assisted transperitoneal aortic lymphadenectomy as part of staging procedure for gynaecological malignancies: single institution experience.** Obstet Gynecol Int. 2013;2013:931318.
62. Garbi A, Colombo N, Aletti G. **Summary of the 18th Biannual Meeting of the European Society of Gynecologic Oncology (ESGO)** Gynecol Oncol. 2014; 132(2):270-2
63. Zapardiel I, Diestro MD, Aletti G **Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes.** Eur J Surg Oncol. 2014;40(4):387-93.
64. Greggi S, Franchi M, Aletti G, Biglia N, Ditto A, Fagotti A, Giorda G, Mangili G, Odicino F, Salerno MG, Vizza E, Scaffa C, Scollo P. **Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology.** Int J Surg. 2014;12(10):1038-44.
65. Bogani G, Cliby WA, Aletti GD. **Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.** Gynecol Oncol. 2015;137(1):167-72
66. Aletti GD, Bristow RE, Chi D, Cliby WA. **There Is Nothing New Under the Sun.** J Clin Oncol. 2015; 20;33(30):3520.
67. Bogani G, Ditto A, Martinelli F, Lorusso D, Chiappa V, Donfrancesco C, Di Donato V, Indini A, Aletti G, Raspagliesi F. **Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis.** Int J Gynecol Cancer. 2016; 26(2):371-80.
68. Zanagnolo V, Minig L, Rollo D, Tomaselli T, Aletti G, Bocciolone L, Landoni F, Cardenas Rebollo JM, Maggioni A. **Clinical and Oncologic Outcomes of Robotic Versus Abdominal Radical Hysterectomy for Women With Cervical Cancer: Experience at a Referral Cancer Center.** Int J Gynecol Cancer. 2016; 26(3):568-74
69. Zanfagnin V, Ferrero A, Biglia N, Aletti G, Gill SE, Makdisi PB, Multinu F, Mariani A. **The role of surgery in recurrent endometrial cancer.** Expert Rev Anticancer Ther. 2016;16(7):741-50

70. Aletti GD, Cliby WA. **Time for centralizing patients with ovarian cancer: what are we waiting for?** Gynecol Oncol. 2016;142(2):209-10
71. Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A. **European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.** Int J Gynecol Cancer. 2016; 26(7):1354-63.
72. Aletti GD, Peiretti M. **Quality control in ovarian cancer surgery.** Best Pract Res Clin Obstet Gynaecol. 2017 May;41:96-107. doi: 10.1016/j.bpobgyn.2016.08.008. Epub 2016 Oct 1.
73. Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, Lecce F, Benedetti Panici P. **Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies.** Ann Surg Oncol. 2017 Jun;24(6):1688-1697. doi: 10.1245/s10434-016-5680-7. Epub 2016 Nov 28.
74. Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, Chiva L, Gabra H, Colombo N, du Bois A. **Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.** J Clin Oncol. 2017 Feb 20;35(6):587-590. doi: 10.1200/JCO.2016.71.0723. Epub 2017 Jan 9.
75. Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A. **European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery.** Int J Gynecol Cancer. 2017 Sep;27(7):1534-1542. doi: 10.1097/IGC.0000000000001041. PMID: 30814245
76. Gadducci A, Carinelli S, Aletti GD. **Neuroendocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists.** Gynecol Oncol 2016, <http://dx.doi.org/10.1016/j.ygyno.2016.12.003>. 2017; 144(3):637-646.
77. Aletti GD, Garbi A, Messori P, Achilarré MT, Zanagnolo V, Rizzo S, Alessi S, Bocciolone L, Landoni F, Biffi R, Carinelli S, Colombo N, Maggioni A. **Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.** Gynecol Oncol. 2017; 144(3):468-473.
78. Uccella S, Bonzini M, Malzoni M, Fanfani F, Palomba S, Aletti G, Corrado G, Ceccaroni M, Seracchioli R, Shakir F, Ferrero A, Berretta R, Tinelli R, Vizza E, Roviglione G, Casarella L, Volpi E, Cicinelli E, Scambia G, Ghezzi F. **The effect of a uterine manipulator on the recurrence and mortality of endometrial cancer: a multi-centric study by the Italian Society of Gynecological Endoscopy.** Am J Obstet Gynecol. 2017 Jun;216(6):592.e1-592.e11.
79. Garbi A, Zanagnolo V, Colombo N, Aletti G, Achilarré MT, Bocciolone L, Landoni F, Rizzo S, Biffi R, Maggioni A. **Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer: Initial Experience at a Tertiary Center.** Int J Gynecol Cancer. 2017; 27(6):1268-1273.
80. Kumar A, Torres ML, Cliby WA, Kalli KR, Bogani G, Aletti G, Nitschmann CC, Multinu F, Weaver AL, Block MS, Mariani A. **Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer.** Anticancer Res. 2017; 37(7):3673-3677
81. Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M,

Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A. **Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.** *Anticancer Res.* 2017; 37(9):5241-5248.

82. Sangiorgio V, Zanagnolo V, Aletti G, Bocciolone L, Bruni S, Landoni F, Colombo N, Maggioni A, Ricciardi E. **Fibroblastic Malignant Peripheral Nerve Sheath Tumour of the Uterine Cervix: Report of a Case and Literature Review With Emphasis on Possible Differential Diagnosis.** *Int J Gynecol Pathol.* 2018; 37(5):497-503.
83. Aletti GD. **Lymphatic Spread of Ovarian Cancer: Can the Anatomical and Pathological Knowledge Help a Personalized Treatment?** *Ann Surg Oncol.* 2018; 25(7):1791-1793.
84. Gadducci A, Carinelli S, Guerrieri ME, Aletti GD. **Melanoma of the lower genital tract: Prognostic factors and treatment modalities.** *Gynecol Oncol.* 2018; 150(1):180-189
85. Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M. **Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.** *Eur Radiol.* 2018; 28(11):4849-4859.
86. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim J, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A. **A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.** *N Engl J Med.* 2019; 380(9):822–832.
87. Gadducci A, Carinelli S, Guerrieri ME, Aletti GD. **Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy.** *Gynecol Oncol.* 2019;153(3):684–693.
88. Aletti G, Laffi A. **Neuroendocrine tumors of the cervix: an urgent call for joining forces.** *Int J Gynecol Cancer.* 2019;29(6):985.
89. Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, Guyon F, Greggi S, Mosgaard BJ, Reinthaller A, Hilpert F, Schade-Brittinger C, Chi DS, Mahner S. **TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).** *Int J Gynecol Cancer.* 2019;29(8):1327–1331.
90. De Piano F, Buscarino V, Maresca D, Maisonneuve P, Aletti G, Lazzari R, Vavassori A, Bellomi M, Rizzo S. **Do DWI and quantitative DCE perfusion MR have a prognostic value in high-grade serous ovarian cancer?.** *Radiol Med.* 2019;124(12):1315–1323.
91. Ricciardi E, Plett H, Sangiorgio V, Paderno M, Landoni F, Aletti G, Prader S, du Bois A, Harter P, Colombo N. **Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series** [published online ahead of print, 2019 Nov 27]. *Int J Gynecol Cancer.* 2019

92. Rizzo S, De Piano F, Buscarino V, Pagan E, Bagnardi V, Zanagnolo V, Colombo N, Maggioni A, Del Grande M, Del Grande F, Bellomi M, Aletti G. **Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study.** Eur J Radiol. 2020 Feb;123:108786. doi: 10.1016/j.ejrad.2019.108786. Epub 2019 Dec 13.
93. Peiretti M, Candotti G, Fais ML, Ricciardi E, Colombo N, Zanagnolo V, Bruni S, Aletti G, Maggioni A. **Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.** Gynecol Oncol. 2020 Apr;157(1):85-88. doi: 10.1016/j.ygyno.2019.12.040. Epub 2020 Jan 15.
94. Gadducci A, Aletti GD. **Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists.** Gynecol Oncol. 2020 Jul;158(1):208-217. doi: 10.1016/j.ygyno.2020.05.021. Epub 2020 May 25.
95. Zanagnolo V, Baroni C, Achilarré MT, Aloisi A, Betella I, Bogliolo S, Garbi A, Maruccio M, Multinu F, Aletti G, Maggioni A. **Oncologic Outcomes of Robotic Radical Hysterectomy (RRH) for Patients with Early-Stage Cervical Cancer: Experience at a Referral Cancer Center.** Ann Surg Oncol. 2021 Mar;28(3):1819-1829. doi: 10.1245/s10434-020-09016-1. Epub 2020 Aug 28.
96. Plett H, Filippova OT, Garbi A, Kommoss S, Rosendahl M, Langstraat C, Phadnis S, Muallem MZ, Baert T, Chi DS, Aletti GD, Taran FA, Ramspott JP, Zivanovic O, du Bois A, Sonoda Y, Gardner G, Traut A, Roche KL, Harter P. **Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.** Gynecol Oncol. 2020 Nov;159(2):434-441. doi: 10.1016/j.ygyno.2020.08.028. Epub 2020 Sep 9.
97. Ceppi L, Grassi T, Galli F, Buda A, Aletti G, Lissoni AA, Adorni M, Garbi A, Colombo N, Bonazzi C, Landoni F, Fruscio R. **Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.** Gynecol Oncol. 2021 Jan;160(1):64-70. doi: 10.1016/j.ygyno.2020.10.014. Epub 2020 Oct 17.
98. Gadducci A, Aletti GD, Landoni F, Lazzari R, Mangili G, Olivas P, Pignata S, Salutati V, Sartori E, Scambia G, Zannoni GF, Sabbatini R, Lorusso D. **Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).** Tumori. 2021 Apr;107(2):100-109. doi: 10.1177/0300891620966382. Epub 2020 Oct 26.
99. Multinu F, Garzon S, Weaver AL, McGree ME, Sartori E, Landoni F, Zola P, Dinoi G, Aletti G, Block MS, Gadducci A, Mariani A. **Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes.** Int J Gynecol Cancer. 2021 Apr;31(4):537-544. doi: 10.1136/ijgc-2020-002094. Epub 2021 Feb 19.
100. Buonomo B, Multinu F, Casarin J, Betella I, Zanagnolo V, Aletti G, Peccatori F. **Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review.** Int J Gynecol Cancer. 2021 Mar;31(3):360-370. doi: 10.1136/ijgc-2020-001774.

101. Maramai M, Achillarre MT, Aloisi A, Betella I, Bogliolo S, Garbi A, Maruccio M, Quatrone C, Aletti GD, Mariani A, Colombo N, Maggioni A, Multinu F, Zanagnolo V. **Cervical re-injection of indocyanine green to improve sentinel lymph node detection in endometrial cancer.** Gynecol Oncol. 2021 Jul;162(1):38-42. doi: 10.1016/j.ygyno.2021.04.026. Epub 2021 Apr 24.
102. Gadducci A, Multinu F, Cosio S, Carinelli S, Ghioni M, Aletti GD. **Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.** Gynecol Oncol. 2021 Sep;162(3):741-750. doi: 10.1016/j.ygyno.2021.06.033.
103. Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, du Bois A; DESKTOP III Investigators. **Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.** N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294.
104. Greggi S, Falcone F, Aletti GD, Cascella M, Bifulco F, Colombo N, Pignata S. **Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups.** J Gynecol Oncol. 2022 Sep;33(5):e60. doi: 10.3802/jgo.2022.33.e60. Epub 2022 Jun 3.
105. Betella I, Fumagalli C, Rafaniello Raviele P, Schivardi G, De Vitis LA, Achillarre MT, Aloisi A, Garbi A, Maruccio M, Zanagnolo V, Aletti G, Guerini-Rocco E, Mariani A, Maggioni A, Barberis M, Colombo N, Multinu F. **A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer.** Int J Gynecol Cancer. 2022 Jun 22;ijgc-2022-003480. doi: 10.1136/ijgc-2022-003480. Online ahead of print.
106. Di Lorenzo P, Conteduca V, Scarpi E, Adorni M, Multinu F, Garbi A, Betella I, Grassi T, Bianchi T, Di Martino G, Amadori A, Maniglio P, Strada I, Carinelli S, Jaconi M, Aletti G, Zanagnolo V, Maggioni A, Savelli L, De Giorgi U, Landoni F, Colombo N, Fruscio R. **Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.** Front Oncol. 2022 Sep 27;12:970918. doi: 10.3389/fonc.2022.970918. eCollection 2022.
107. Plett H, Ricciardi E, Vacaru V, Ramspott JP, Colombo N, Sehouli J, du Bois A, Garbi A, Richter R, Ataseven B, Aletti G, Braicu E, Heitz F, Portuesi R, Muallem MZ, Dages T, Parma G, Roser E, Traut A, Multinu F, Harter P. **Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.** Int J Gynecol Cancer. 2023 Feb 9;ijgc-2022-003854. doi: 10.1136/ijgc-2022-003854. Online ahead of print. PMID: 36759002
108. Mohammad A, Ainio C, Narasimhulu DM, McGree M, Weaver AL, Kumar A, Garbi A, Mariani A, Aletti G, Multinu F, Langstraat C, Cliby W. **Comparison of the Contracted Accordion, Expanded Accordion, and Clavien-Dindo complication grading scales after ovarian cancer cytoreduction.** Int J Gynecol

Cancer. 2023 Feb 7:ijgc-2022-003962. doi: 10.1136/ijgc-2022-003962. Online ahead of print. PMID: 36750269

109. Gadducci A, Multinu F, De Vitis LA, Cosio S, Carinelli S, Aletti GD. **Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes.** Gynecol Oncol. 2023 Apr;171:95-105. doi: 10.1016/j.ygyno.2023.02.009. Epub 2023 Feb 24.
110. Caruso G, Tomao F, Parma G, Lapresa M, Multinu F, Palaia I, Aletti G, Colombo N. **Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions.** Int J Gynecol Cancer. 2023 Apr 3;33(4):431-443. doi: 10.1136/ijgc-2022-004149.
111. Valenza C, Spada F, Multinu F, Benini L, Borghesani M, Algeri L, Rubino M, Pisa E, Gervaso L, Cella CA, Carinelli S, Bruni S, Schivardi G, Curigliano G, Zanagnolo V, Aletti G, Colombo N, Fazio N. **Multimodal treatment for resectable neuroendocrine carcinoma of the cervix.** Endocr Relat Cancer. 2023 Aug 14;30(10):e230112. doi: 10.1530/ERC-23-0112.
112. Caruso G, Coleman RL, Aletti G, Multinu F, Botticelli A, Palaia I, Cliby W, Colombo N. **Systemic therapy de-escalation in advanced ovarian cancer: a new era on the horizon?** Int J Gynecol Cancer. 2023 Sep 4;33(9):1448-1457. doi: 10.1136/ijgc-2023-004740.
113. Schivardi G, Casarin J, Habermann EB, Bews KA, Langstraat CL, Cliby W, Cucinella G, De Vitis LA, Ramirez PT, Aletti GD, Mariani A, Multinu F. **Practice patterns and complications of hysterectomy for invasive cervical cancer after the Laparoscopic Approach to Cervical Cancer trial.** Am J Obstet Gynecol. 2024 Jan;230(1):69.e1-69.e10. doi: 10.1016/j.ajog.2023.09.002.
114. Caruso G, Bruni S, Lapresa M, De Vitis LA, Parma G, Minicucci V, Betella I, Schivardi G, Peccatori F, Lazzari R, Cliby W, Aletti GD, Zanagnolo V, Maggioni A, Colombo N, Multinu F. **Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature review.** Int J Gynecol Cancer. 2023 Nov 10:ijgc-2023-004928. doi: 10.1136/ijgc-2023-004928.
115. De Vitis LA, Schivardi G, Caruso G, Fumagalli C, Vacirca D, Achilarré MT, Aloisi A, Garbi A, Zanagnolo V, Aletti G, Guerini-Rocco E, Mariani A, Maggioni A, Barberis M, Bogani G, Colombo N, Multinu F, Betella I. **Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.** Int J Gynecol Cancer. 2023 Dec 22:ijgc-2023-004864. doi: 10.1136/ijgc-2023-004864.
116. Loverro M, Aloisi A, Tortorella L, Aletti GD, Kumar A. **Trends and current aspects of reconstructive surgery for gynecological cancers.** Int J Gynecol Cancer. 2024 Mar 4;34(3):426-435. doi: 10.1136/ijgc-2023-004620.
117. De Vitis LA, Fumagalli D, Schivardi G, Capasso I, Grcevic L, Multinu F, Cucinella G, Occhiali T, Betella I, Guillot BE, Pappalettera G, Shahi M, Fought AJ, McGree M, Reynolds E, Colombo N, Zanagnolo V, Aletti G, Langstraat C, Mariani A, Glaser G. **Incidence of sentinel lymph node metastases in apparent**

early-stage endometrial cancer: a multicenter observational study. Int J Gynecol Cancer. 2024 May 6;34(5):689-696. doi: 10.1136/ijgc-2023-005173.

118. Mohammad A, Ainio C, Narasimhulu DM, McGree M, Weaver AL, Kumar A, Garbi A, Mariani A, Aletti G, Multinu F, Langstraat C, Cliby W. **Measuring the impact of specific surgical complications after ovarian cancer cytoreductive surgery on short-term outcomes.** Int J Gynecol Cancer. 2024 Aug 5;34(8):1240-1245. doi: 10.1136/ijgc-2024-005456.
119. Golia D'Augè T, Caruso G, Laudani ME, Nazzaro L, De Vitis LA, Rosanu NM, Ribero L, Alessi S, Lazzari R, Betella I, Aletti G, Zanagnolo V, Colombo N, Schivardi G, Multinu F. **Para-aortic lymph node recurrence in surgically treated early-stage cervical cancer without para-aortic lymph node surgical staging.** Int J Gynecol Cancer. 2024 Dec 2;34(12):1867-1873. doi: 10.1136/ijgc-2024-005950.
120. Caruso G, Langstraat CL, Kumar A, McGree ME, Fought AJ, Nasioudis D, Aletti GD, Colombo N, Giuntoli RL, Cliby WA. **Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.** Gynecol Oncol. 2024 Dec;191:86-94. doi: 10.1016/j.ygyno.2024.09.018. Epub 2024 Oct 3. PMID: 39366034
121. Fagotti A, Costantini B, Fanfani F, Giannarelli D, De Iaco P, Chiantera V, Mandato V, Giorda G, Aletti G, Greggi S, Perrone AM, Salutati V, Trozzi R, Scambia G. **Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).** J Clin Oncol. 2025 Mar;43(7):852-860. doi: 10.1200/JCO.24.00686. Epub 2024 Nov 21. PMID: 39571127
122. Barcellini A, Fontana G, Vai A, Aletti GD, Charalampopoulou A, Chiellino S, Ditto A, Landoni F, Locati LD, Mangili G, Martinelli F, Piccolo F, Franzetti J, Imperato S, Raspagliesi F, Orlandi E. **Investigating the Local Effectiveness of Carbon Ion Radiotherapy for Unresectable Female Genital Tract Melanomas: A Preliminary Real-World Study.** Cancers (Basel). 2024 Dec 12;16(24):4147. doi: 10.3390/cancers16244147. PMID: 39766046
123. De Vitis LA, Reyes-Baez FE, Schivardi G, Shahi M, Fought AJ, McGree ME, Capasso I, Grceвич L, Betella I, Ghioni M, Guerini-Rocco E, Aletti GD, Cliby W, Multinu F, Langstraat CL, Mariani A, Glaser GE. **Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.** Gynecol Oncol. 2025 Feb;193:81-88. doi: 10.1016/j.ygyno.2024.12.013. Epub 2025 Jan 10. PMID: 39798193
124. De Vitis LA, Schivardi G, Delfrati S, Biffi B, Viscardi A, Rosanu M, Ribero L, Caruso G, Rappa A, Marinucci L, Adorisio R, Zanagnolo V, Aletti GD, Barberis M, Guerini-Rocco E, Peccatori FA, Urbinati AV, Pino I, Franchi D, Betella I, Colombo N, Multinu F. **The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment.** Int J Gynecol Cancer. 2025 Jan;35(1):100024. doi: 10.1016/j.ijgc.2024.100024. Epub 2024 Dec 18. PMID: 39878279
125. Gaba F, Blyuss O, Ash K; GO SOAR Collaborators. **Survival after interval and delayed cytoreduction surgery in advanced ovarian cancer: a Global Gynaecological Oncology Surgical Outcomes**

Collaborative-Led Study (GO SOAR2). Int J Gynecol Cancer. 2025 Apr;35(4):101650. doi: 10.1016/j.ijgc.2025.101650. Epub 2025 Jan 22. PMID: 39955177

126. Trillsch F, Czogalla B, Mahner S, Loidl V, Reuss A, du Bois A, Sehouli J, Raspagliesi F, Meier W, Cibula D, Mustea A, Runnebaum IB, Schmalfeldt B, Aletti G, Kimmig R, Scambia G, Hilpert F, Hasenburg A, Wagner U, Harter P. **Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis.** Int J Surg. 2025 Apr 1;111(4):2914-2922. doi: 10.1097/JS9.0000000000002306. PMID: 39992106
127. De Vitis LA, Schivardi G, Grcevich L, Capasso I, Fumagalli D, Dahal S, Lembo A, Breitkopf DM, Laughlin-Tommaso SK, Fought AJ, Johnson NE, Caserta MP, Clingan JJ, Aletti GD, Mariani A, Packard AT, Langstraat CL. **Diagnostic Algorithms for Adnexal Masses in the Hands of a Novice Operator.** Obstet Gynecol. 2025 Apr 1;145(4):368-376. doi: 10.1097/AOG.0000000000005853. Epub 2025 Feb 27. PMID: 40014861
128. Fumagalli D, Jayraj A, Olearo E, Capasso I, Hsu HC, Tzur Y, Piedimonte S, Jugeli B, Santana BN, De Vitis LA, Caruso G, Aletti G, Colombo N, Ramirez PT. **Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer.** Int J Gynecol Cancer. 2025 Mar;35(3):101664. doi: 10.1016/j.ijgc.2025.101664. Epub 2025 Jan 28. PMID: 40022844
129. Caruso G, Kumar A, Langstraat CL, McGree ME, Fought AJ, Harrington S, Nasioudis D, Aletti GD, Colombo N, Giuntoli RL, Cliby W. **Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.** Gynecol Oncol. 2025 Apr;195:106-114. doi: 10.1016/j.ygyno.2025.03.016. Epub 2025 Mar 15. PMID: 40090176
130. De Vitis LA, Schivardi G, Gaeta A, Caruso G, Rosanu M, Ribero L, Fumagalli D, Casarin J, Betella I, Bogani G, Langstraat CL, Aletti GD, Colombo N, Zanagnolo V, Gandini S, Multinu F. **External validation of the annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.** Int J Gynecol Cancer. 2025 Mar 1:101756. doi: 10.1016/j.ijgc.2025.101756. Online ahead of print. PMID: 40140271
131. Caruso G, Gaiano M, De Vitis LA, Stefani E, Rosanu M, Ribero L, Alessi S, Petralia G, Casarin J, Gandini S, Maggioni A, Aletti GD, Zanagnolo V, Colombo N, Schivardi G, Multinu F. **Predictors of recurrence in early-stage cervical cancer without adjuvant treatment after radical surgery.** Eur J Surg Oncol. 2025 May 5;51(8):110121. doi: 10.1016/j.ejso.2025.110121. Online ahead of print. PMID: 40347713
132. Ainio C, Rosanu M, Ribero L, Caruso G, De Vitis LA, Kumar A, Langstraat CL, McGree ME, Multinu F, Ostby SA, Schivardi G, Tapia AL, Aletti GD, Cliby WA. **Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer.** Gynecol Oncol. 2025 Aug;199:133-138. doi: 10.1016/j.ygyno.2025.06.024. Epub 2025 Jul 7. PMID: 40628173.
133. Giudici A, Schivardi G, Meschini T, Restaino S, Mariani A, Bogani G, Raspagliesi F, Fumagalli D, Ribero L, Multinu F, Vizzielli G, Zanagnolo V, Aletti GD, Ghezzi F, Casarin J. **Detection rate of sentinel lymph**

nodes in early-stage endometrial cancer according to age. Eur J Surg Oncol. 2025 Oct;51(10):110380.
doi: 10.1016/j.ejso.2025.110380. Epub 2025 Aug 12. PMID: 40829382.